- Home
- RLTY vs OKUR Comparison
RLTY vs OKUR Comparison
Compare RLTY & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- OKUR
- Stock Information
- Founded
- RLTY 2022
- OKUR 2011
- Country
- RLTY United States
- OKUR United States
- Employees
- RLTY N/A
- OKUR N/A
- Industry
- RLTY Investment Managers
- OKUR
- Sector
- RLTY Finance
- OKUR
- Exchange
- RLTY Nasdaq
- OKUR NYSE
- Market Cap
- RLTY 277.8M
- OKUR 234.2M
- IPO Year
- RLTY N/A
- OKUR N/A
- Fundamental
- Price
- RLTY $15.67
- OKUR $16.60
- Analyst Decision
- RLTY
- OKUR Strong Buy
- Analyst Count
- RLTY 0
- OKUR 2
- Target Price
- RLTY N/A
- OKUR $37.50
- AVG Volume (30 Days)
- RLTY 86.7K
- OKUR 63.1K
- Earning Date
- RLTY 01-01-0001
- OKUR 11-07-2024
- Dividend Yield
- RLTY 9.35%
- OKUR N/A
- EPS Growth
- RLTY N/A
- OKUR N/A
- EPS
- RLTY N/A
- OKUR N/A
- Revenue
- RLTY N/A
- OKUR N/A
- Revenue This Year
- RLTY N/A
- OKUR N/A
- Revenue Next Year
- RLTY N/A
- OKUR N/A
- P/E Ratio
- RLTY N/A
- OKUR N/A
- Revenue Growth
- RLTY N/A
- OKUR N/A
- 52 Week Low
- RLTY $11.38
- OKUR $9.80
- 52 Week High
- RLTY $14.60
- OKUR $77.60
- Technical
- Relative Strength Index (RSI)
- RLTY 35.97
- OKUR N/A
- Support Level
- RLTY $15.81
- OKUR N/A
- Resistance Level
- RLTY $16.79
- OKUR N/A
- Average True Range (ATR)
- RLTY 0.34
- OKUR 0.00
- MACD
- RLTY -0.06
- OKUR 0.00
- Stochastic Oscillator
- RLTY 15.94
- OKUR 0.00
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.